Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966559 | PMC |
| http://dx.doi.org/10.4103/0974-2700.70740 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathological diagnosis of central nervous system tumours in adults: what's new?
Pathology
December 2024
Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
In the course of the last decade, the pathological diagnosis of many tumours of the central nervous system (CNS) has transitioned from a purely histological to a combined histological and molecular approach, resulting in a more precise 'histomolecular diagnosis'. Unfortunately, translation of this refinement in CNS tumour diagnostics into more effective treatment strategies is lagging behind. There is hope though that incorporating the assessment of predictive markers in the pathological evaluation of CNS tumours will help to improve this situation.
View Article and Find Full Text PDFImpulse control disorders in Parkinson's disease: What's new?
J Neurol
January 2025
Parkinson's Disease Research Clinic, Macquarie University, 75 Talavera Road, Sydney, NSW, 2109, Australia.
Impulse Control Disorders (ICDs) are increasingly recognized as a significant non-motor complication in Parkinson's disease (PD), impacting patients and their caregivers. ICDs in PD are primarily associated with dopaminergic treatments, particularly dopamine agonists, though not all patients develop these disorders, indicating a role for genetic and other clinical factors. Studies over the past few years suggest that the mesocorticolimbic reward system, a core neural substrate for impulsivity, is a key contributor to ICDs in PD.
View Article and Find Full Text PDF[Pneumology : what's new in 2024].
Rev Med Suisse
January 2025
Faculté de biologie et médecine, Université de Lausanne, 1005 Lausanne.
In 2024, several important innovations have enriched the management of respiratory diseases, including pulmonary hypertension, tuberculosis, COPD, and obstructive sleep apnea syndrome (OSAS). Notable advancements include the introduction of sotatercept in Switzerland for pulmonary arterial hypertension and mediastinal cryobiopsies, reflecting a shift toward more personalized medicine. Meanwhile, biologic therapies for COPD offer promising perspectives, and a potential path is emerging for shortening the treatment of certain forms of tuberculosis.
View Article and Find Full Text PDF[Ophthalmology : what's new in 2024].
Rev Med Suisse
January 2025
Service d'ophtalmologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Ophthalmology is notable for significant technological innovations (e.g laser, microscopy…) that allow for diagnostic and therapeutic advances every year. This article presents the main significant therapeutic progress and highlights the growing use of artificial intelligence in diagnosis of eye disease.
View Article and Find Full Text PDF[Emergency medicine : what's new in 2024].
Rev Med Suisse
January 2025
Service des urgences, Département des centres interdisciplinaires, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Emergency medicine plays a crucial vital role as the gateway to the Swiss healthcare system. Although it has not yet been officially recognized with a specialist title, unlike most European countries - emergency medicine in Switzerland is characterized by robust research activity. This scientific article demonstrates a dynamic and rigorous evolution.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!